Quantitation of Residual Single Chain Protein Unprocessed by Endogenous Protease in Botulinum Toxin Serotype A Using CE-SDS
Program: Applied Biotechnology Master's Degree — Quality Assurance and Compliance
Host Company: Revance Therapeutics
Location: Newark, California (onsite)
Student: Frank Chang
Establishment of a superior quantitation tool for the residual inactive botulinum toxin serotype A (single chain) in biopharmaceutical manufacturing.